SEATTLE, WA – Biotech firm Absci, known for its AI-powered drug discovery platform, has issued an unprecedented pre-announcement regarding its fourth-quarter 2025 earnings call, assuring investors that the event will feature “a significant amount of executive mumbling, interspersed with prolonged, uncomfortable silences.” The company stated this proactive disclosure was part of its commitment to “radical transparency” regarding future performance communication.

“We understand that investors crave clarity, and while the exact financial figures for Q4 2025 are, shall we say, still in flux, we can definitively forecast the general tenor of the call,” stated Absci’s Head of Investor Relations, Brenda Finch, in a press release. “Our CEO is already practicing his ‘thoughtful gaze into the middle distance’ for when tough questions arise, and our CFO is perfecting the art of shuffling papers loudly to buy time.”

Analysts lauded the move as a refreshing, albeit concerning, level of honesty. “It’s bold,” commented market strategist Dr. Evan Thorne. “Usually, companies wait until the actual call to deliver vague answers and non-committal projections. Absci is simply cutting out the middleman, letting everyone know now that their future financial disclosures will largely consist of audible hesitations and the occasional throat-clearing.”

Sources close to the company indicate that preparations are already underway, including executive speech coaching focused on phrases like “we’re exploring synergies,” “optimizing our burn rate,” and “pivoting towards… something.” The company also plans to introduce a new AI model specifically designed to generate plausible-sounding but ultimately meaningless corporate jargon for difficult questions.

The pre-announcement concluded by reassuring shareholders that despite the anticipated mumbling, Absci remains “extremely bullish on the long-term potential of our proprietary intellectual property, whatever that turns out to be.”